Leczenie niedrobnokomórkowego raka płuca (NDRP) w stadium zaawansowania miejscowego lub rozsiewu w kontekście programu lekowego

• Authors: Dariusz M. Kowalski , Paweł Krawczyk

Title variants

EN

Advanced or metastatic non-small-cell lung cancer treatment – new Polish government regulation

• Languages of publication: PL

Abstracts

PL

W artykule przedstawiono aktualne zalecenia leczenia niedrobnokomórkowego raka płuca wobec ustaleń aktualnie obowiązującego programu lekowego.

EN

The article presents the non-small-cell lung cancer current treatment recommendations in consideration of Polish government regulation.

Keywords

EN

NDRP; docetaksel; erlotynib; gefitynib; pemetreksed; program lekowy

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2013
• Volume: 3
• Issue: 2
• Pages: 96-101

Contributors

author

Dariusz M. Kowalski

• Klinika Nowotworów Płuca i Klatki Piersiowej Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie

author

Paweł Krawczyk

• Katedra i Klinika Pneumonologii, Onkologii i Alergologii, Uniwersytet Medyczny w Lublinie

References

• Pignon J.P., Tribodet H., Scagliotti G.V. et al.: Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. J. Clin. Oncol. 2008; 26 (21): 3552-3559.
• Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998; 352(9124): 257-263.
• Scagliotti G.V., Pastorino U., Vansteenkiste J.F. et al.: Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2012; 30: 172-178.
• Aupérin A., Le Péchoux C., Rolland E. et al.: Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2010; 28: 2181-2190.
• Delbaldo C., Michiels S., Syzi N. et al.: Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non-Small-Cell Lung Cancer: A Meta-analysis. JAMA 2004; 292: 470-484.
• Boni C., Tiseo M., Boni L. et al.: Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). Br. J. Cancer 2012; 106: 658-665.
• Scagliotti G.V., Parikh P., von Pawel J. et al.: Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy- Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2008; 21: 3543-3551.
• Jassem J., Biernat W., Drosik K. et al.: Updated recommendations on systemic treatment of non-small cell lung cancer and malignant pleural mesothelioma. Pneumonol. Alergol. Pol. 2010; 78(6): 418-431.
• Petrelli F., Borgonovo K., Cabiddui M. et al.: Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials. Clin. Lung Cancer 2012; 13: 107-114.
• Hui G., Xin D., Dong W. et al.: Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis. Transl. Lung Cancer Res. 2012; 1(2): 129-144.
• Di Maio M., Chiodini P., Georgoulias V. et al.: Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2009; 27(11): 1836-1843.
• [online: www.nfz.gov.pl].

• Document Type: article